Aligos Therapeutics completes stock option exchange; 93% of eligible underwater options surrendered.

Aligos Therapeutics, Inc.

Option exchange program closed; 3,880,332 shares surrendered (~93% of eligible) for 1,906,153 replacement options.
CEO Lawrence M. Blatt surrendered 854,250 options, received 421,100 replacement options; other NEOs and directors also participated.
Exchange ratios were 1.4-for-1 or 3.4-for-1 based on exercise price; all surrendered options were underwater.
Replacement options have a new one-year cliff vest from grant date (Feb 28, 2024), then follow original schedule.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.